Related Experiment Video
Updated: May 26, 2026

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
Published on: June 9, 2022
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A
Chunfu Wang1, Lingling Jia, Haichang Huang
1Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.
Abstract:
The antiviral profile of BMS-790052, a potent hepatitis C virus (HCV) replication complex inhibitor targeting nonstructural protein NS5A, is well characterized for HCV genotype-1. Here, we report that BMS-790052 inhibits hybrid replicons containing HCV genotype-4 NS5A genes with 50% effective concentrations (EC(50)s) ranging from 7 to 13 pM. NS5A residue 30 was an important site for BMS-790052-selected resistance in the hybrid replicons. Our results support the potential of BMS-790052 as a valuable component of combination therapy for HCV genotype-4 chronic infection.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis

